Clinical scoring systems in meningococcal disease.

Methods Mol Med

Department of Pediatric Intensive Care, The New Children's Hospital, Westmead, Australia.

Published: October 2012

Scoring systems used in meningococcal disease have been developed and validated to predict death or severity of illness in cohorts of patients, usually in the setting of intensive care. When using these scores, it is important to remember that any individual's score is only of limited value in prognosticating about that individual patient and can be misleading (1). The accuracy of any score is determined by how well its estimated pattern of mortality compares with that observed in the score's developmental cohort, rather than in individual patients. Scores cannot be considered interchangeable; different scores, comprised of different sets of variables to arrive at the probability of mortality, may arrive at the same overall aggregate risk of mortality in a population of patients with meningococcal disease, despite individual estimates within this cohort of patients differing widely between scores. The ability of a score to predict death for patients who die and survival for those that live is best-described by the area under the receiver operator characteristic (ROC) curve (2). This curve is a plot of sensitivity versus "(1 -specificity)", i.e., the true-positive to false-positive fractions, at different decision thresholds. The greater the discriminative ability of a test, the closer the area under the curve comes towards 1.0, where the true-positive fraction is 1.0 or 100% (perfect specificity) and the false-positive fraction is 0 (perfect sensitivity). No score, however, has sufficient accuracy for individual prognostication and the use of scores in this way is inappropriate for clinical practice or research (3).

Download full-text PDF

Source
http://dx.doi.org/10.1385/1-59259-149-3:411DOI Listing

Publication Analysis

Top Keywords

meningococcal disease
12
scoring systems
8
systems meningococcal
8
predict death
8
patients
5
scores
5
clinical scoring
4
disease scoring
4
disease developed
4
developed validated
4

Similar Publications

IgA1 protease is one of the virulence factors of , and other pathogens causing bacterial meningitis. The aim of this research is to create recombinant proteins based on fragments of the mature IgA1 protease A-P from serogroup B strain H44/76. These proteins are potential components of an antimeningococcal vaccine for protection against infections caused by pathogenic strains of and other bacteria producing serine-type IgA1 proteases.

View Article and Find Full Text PDF

Background: This study aims to evaluate parents' knowledge about vaccination targeted for adolescents.

Methods: The cross-sectional survey was conducted between February and April 2024 in a sample of parents of adolescents attending middle and high schools in Southern Italy.

Results: Only 10.

View Article and Find Full Text PDF

Characterization of Unusual Serogroups of .

Microorganisms

December 2024

Institut Pasteur, Invasive Bacterial Infections, Université Paris Cité, 75015 Paris, France.

Most cases of invasive meningococcal disease (IMD) in Europe are caused by isolates of the serogroups B, C, W, and Y. We aimed to explore cases caused by other unusual serogroups. We retrospectively screened IMD cases in the databases of the National Reference Center for Meningococci and in France between 2014 and 2023.

View Article and Find Full Text PDF

The genus Neisseria includes two major human pathogens: N. meningitidis causing bacterial meningitis/septicemia and N. gonorrhoeae causing gonorrhoea.

View Article and Find Full Text PDF

Post-Marketing Surveillance of Adverse Events Following Meningococcal Vaccination - China, 2013-2021.

China CDC Wkly

December 2024

National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.

What Is Already Known About This Topic?: From 2010 to 2012, the incidence of adverse vaccine reactions from meningococcal vaccine (MenV) in China ranged from 8.46 to 56.30 per 100,000 doses.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!